Analytical Data
-
Gene name
AKR1C4
- Application
-
Alternative Names
3-alpha-HSD1 3-alpha-hydroxysteroid dehydrogenase type I Chlordecone reductase
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P17516
-
Expression Region
1-323aa
-
Molecular Weight
64.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AKR1C4, also known as Aldo-Keto Reductase 1C4, is a member of the aldo-keto reductase (AKR) superfamily, which plays a vital role in the metabolism of endogenous and exogenous compounds. This enzyme is involved in the reduction of steroid hormones, such as androgens and corticosteroids, influencing various physiological processes including reproduction, stress response, and inflammation. Dysregulation of AKR1C4 has been implicated in several diseases, including hormone-dependent cancers, metabolic disorders, and cardiovascular diseases. Given its significance in these pathological conditions, research into AKR1C4 recombinant proteins has gained traction. The production of recombinant AKR1C4 allows for detailed biochemical characterizations, such as substrate specificity and enzyme kinetics, and facilitates the exploration of its potential as a therapeutic target. By investigating the structure-function relationship of AKR1C4, scientists aim to uncover the mechanistic pathways involving this enzyme and develop strategies for modulating its activity. Additionally, recombinant forms of the enzyme can be utilized in drug metabolism studies to predict the pharmacokinetics of therapeutic agents metabolized by the AKR pathway. This area of research not only enhances our understanding of AKR1C4 but also paves the way for novel therapeutic approaches leveraging this enzyme's unique properties.
